The interface between systemic sclerosis and cancer has offered valuable insights into our understanding of systemic sclerosis disease pathogenesis. Defining systemic sclerosis subgroups both temporally and serologically has been instrumental in stratifying cancer risk, with autoantibodies to RNA polymerase 3, RNA polymerase 1 large subunit, RNA binding region containing 3, and centromere identifying subgroups at increased or decreased risk of cancer. Clinically, improved subgrouping of systemic sclerosis patients provides the opportunity to detect cancer at earlier stages of disease while increasing our efficiency of cancer assessment. Additional studies are needed to define the optimal approach to cancer screening in systemic sclerosis, and validation studies in different cohorts will be needed to confirm all findings.
RoummADMedsgerTA. Cancer and systemic sclerosis: an epidemiologic study. Arthritis Rheum1985; 28(12): 1336–1340.
2.
Abu-ShakraMGuilleminFLeeP. Cancer in systemic sclerosis. Arthritis and Rheum1993; 36(4): 460–464.
3.
RosenthalAKMcLaughlinJKLinetMS, et al. Scleroderma and malignancy: an epidemiological study. Ann Rheum Dis1993; 52(7): 531–533.
4.
RosenthalAKMcLaughlinJKGridleyG, et al. Incidence of cancer among patients with systemic sclerosis. Cancer1995; 76(5): 910–914.
5.
HillCLNguyenAMRoderD, et al. Risk of cancer in patients with scleroderma: a population based cohort study. Ann Rheum Dis2003; 62(8): 728–731.
6.
DerkCTRasheedMArtlettCM, et al. A cohort study of cancer incidence in systemic sclerosis. J Rheumatol2006; 33(6): 1113–1116.
7.
KangKYYimHWKimIJ, et al. Incidence of cancer among patients with systemic sclerosis in Korea: results from a single centre. Scand J Rheumatol2009; 38(4): 299–303.
8.
OlesenABSvaerkeCFarkasDK, et al. Systemic sclerosis and the risk of cancer: a nationwide population-based cohort study. Br J Dermatol2010; 163(4): 800–806.
9.
SiauKLaversuchCJCreamerP, et al. Malignancy in scleroderma patients from south west England: a population-based cohort study. Rheumatol Int2011; 31(5): 641–645.
10.
HashimotoAArinumaYNagaiT, et al. Incidence and the risk factor of malignancy in Japanese patients with systemic sclerosis. Intern Med2012; 51(13): 1683–1688.
11.
KuoCFLuoSFYuKH, et al. Cancer risk among patients with systemic sclerosis: a nationwide population study in Taiwan. Scand J Rheumatol2012; 41(1): 44–49.
12.
BonifaziMTramacereIPomponioG, et al. Systemic sclerosis (scleroderma) and cancer risk: systematic review and meta-analysis of observational studies. Rheumatology2013; 52(1): 143–154.
13.
OnishiASugiyamaDKumagaiS, et al. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum2013; 65(7): 1913–1921.
14.
ZhangJQWanYNPengWJ, et al. The risk of cancer development in systemic sclerosis: a meta-analysis. Cancer Epidemiol2013; 37(5): 523–527.
15.
ChatterjeeSDombiGWSeversonRK, et al. Risk of malignancy in scleroderma: a population-based cohort study. Arthritis Rheum2005; 52(8): 2415–2424.
16.
ShahAACasciola-RosenL. Mechanistic and clinical insights at the scleroderma-cancer interface. J Scleroderma Relat Disord2017; 2(3): 153–159.
17.
Bernal-BelloDde TenaJGGuillen-Del CastilloA, et al. Novel risk factors related to cancer in scleroderma. Autoimmun Rev2017; 16(5): 461–468.
18.
ShahAACasciola-RosenLRosenA. Review: cancer-induced autoimmunity in the rheumatic diseases. Arthritis Rheumatol2015; 67(2): 317–326.
19.
NikpourMHissariaPByronJ, et al. Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. Arthritis Res Ther2011; 13(6): R211.
20.
De LucaGBoselloSLBerardiG, et al. Tumour-associated antigens in systemic sclerosis patients with interstitial lung disease: association with lung involvement and cancer risk. Rheumatology2015; 54(11): 1991–1999.
21.
PontifexEKHillCLRoberts-ThomsonP. Risk factors for lung cancer in patients with scleroderma: a nested case-control study. Ann Rheum Dis2006; 66(4): 551–553.
22.
IgusaTHummersLKVisvanathanK, et al. Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer. Ann Rheum Dis2018; 77(8): 1179–1186.
23.
HiguchiMHoriuchiTIshibashiN, et al. Anticentromere antibody as a risk factor for cancer in patients with systemic sclerosis. Clin Rheumatol2000; 19(2): 123–126.
24.
KasifogluTYasar BilgeSYildizF, et al. Risk factors for malignancy in systemic sclerosis patients. Clin Rheumatol2016; 35(6): 1529–1533.
25.
DerkCTSakkasLIRasheedM, et al. Autoantibodies in patients with systemic sclerosis and cancer: a case-control study. J Rheumatol2003; 30(9): 1994–1996.
26.
ShahAARosenAHummersL, et al. Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum2010; 62(9): 2787–2795.
27.
JosephCGDarrahEShahAA, et al. Association of the Autoimmune Disease Scleroderma with an Immunologic Response to Cancer. Science2014; 343(6167): 152–157.
28.
Airo’PCeribelliACavazzanaI, et al. Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies. J Rheumatol2011; 38(7): 1329–1334.
29.
MoinzadehPFonsecaCHellmichM, et al. Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma. Arthritis Res Ther2014; 16(1): R53.
30.
LazzaroniM-GCavazzanaIColomboE, et al. Malignancies in patients with anti-RNA polymerase III antibodies and systemic sclerosis: analysis of the EULAR scleroderma trials and research cohort and possible recommendations for screening. J Rheumatol2017; 44(5): 639–647.
31.
SaigusaRAsanoYNakamuraK, et al. Association of anti-RNA polymerase III antibody and malignancy in Japanese patients with systemic sclerosis. J Dermatol2015; 42(5): 524–527.
32.
ShahAAHummersLKCasciola-RosenL, et al. Examination of autoantibody status and clinical features associated with cancer risk and cancer-associated scleroderma. Arthritis Rheumatol2015; 67(4): 1053–1061.
33.
AtalayCAtalayGYilmazKB, et al. The role of anti-CENP-B and anti-SS-B antibodies in breast cancer. Neoplasma2005; 52(1): 32–35.
34.
AtalayCDoganLAtalayG. Anti-CENP-B antibodies are associated with prolonged survival in breast cancer. Future Oncol2010; 6(3): 471–477.
35.
FritzlerMJRattnerJBLuftLM, et al. Historical perspectives on the discovery and elucidation of autoantibodies to centromere proteins (CENP) and the emerging importance of antibodies to CENP-F. Autoimmun Rev2011; 10(4): 194–200.
36.
HansenJEChanGLiuY, et al. Targeting cancer with a lupus autoantibody. Sci Transl Med2012; 4(157): 157ra142.
37.
XuGJShahAALiMZ, et al. Systematic autoantigen analysis identifies a distinct subtype of scleroderma with coincident cancer. Proc Natl Acad Sci U S A2016; 113(47): E7526–E7534.
38.
ShahAAXuGRosenA, et al. Brief report: anti-RNPC-3 antibodies as a marker of cancer-associated scleroderma. Arthritis Rheumatol2017; 69(6): 1306–1312.
39.
ShahAALaihoMRosenA, et al. Scleroderma patients with antibodies against the large subunits of both RNA polymerases-I and -III are protected against cancer. Arthritis Rheumatol2019; 71: 1571–1579.
40.
StetlerDAReichlinMBerlinCM, et al. Autoantibodies against RNA polymerase I in scleroderma and Sjögren’s syndrome scera. Biochem Biophys Res Commun1987; 144(3): 1296–1302.
41.
ReimerGRoseKMScheerU, et al. Autoantibody to RNA polymerase I in scleroderma sera. J Clin Invest1987; 79(1): 65–72.
42.
PeltonenKColisLLiuH, et al. A targeting modality for destruction of RNA polymerase I that possesses anticancer activity. Cancer Cell2014; 25(1): 77–90.
LoebSSandaMGBroylesDL, et al. The prostate health index selectively identifies clinically significant prostate cancer. J Urol2015; 193(4): 1163–1169.
46.
TosoianJJDruskinSCAndreasD, et al. Prostate health index density improves detection of clinically significant prostate cancer. BJU Int2017; 120(6): 793–798.
